Note: Ingredients listed on restricted chemical lists
EC/CAS
21645-51-2
Name of the chemical
Aluminium hydroxide
Concentration
1-5
EC/CAS
1675-54-3
Name of the chemical
2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bisoxirane
Concentration
1-5
EC/CAS
61788-32-7
Name of the chemical
Terphenyl, hydrogenated
Concentration
0.5-1.5
EC/CAS
13463-67-7
Name of the chemical
Reaction mass of titanium dioxide and silver chloride
Concentration
0.1-1
General Information
Version
20
Revision date
2025-12-19
Product name
PR 2001 B 2 (MF)
1.2.1 Relevant identified uses
Industrial applications
Manufacturer Name
PPG Aerospace PRC-DeSoto
Icons in SDS
Company Information
company name
PPG Aerospace PRC-DeSoto
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H317, H351
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
Ingredient(s) with unknown acute toxicity
55% (oral), 60.9% (dermal), 89.9% (inhalation)
Signal word
Warning
Hazard statements
May cause an allergic skin reaction. Suspected of causing cancer.
Prevention
Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Wear protective gloves, protective clothing and eye or face protection. Avoid breathing dust. Contaminated work clothing must not be allowed out of the workplace.
Response
IF exposed or concerned Get medical advice or attention. IF ON SKIN Wash with plenty of water. If skin irritation or rash occurs: Get medical advice or attention. Take off contaminated clothing and wash it before reuse.
Storage
Store locked up.
Disposal
Dispose of contents and container in accordance with all local, regional, national and international regulations.
Supplemental label elements
Emits toxic fumes when heated.
2.3 Other hazards
None known.
2.1 Classification of the substance or mixture
substance or mixture CARCINOGENICITY - Category 2 Percentage of the mixture consisting of ingredient(s) of unknown acute toxicity: 55% (oral), 60.9% (dermal), 89.9% (inhalation)
